AI-extracted from the 10-Q filed 2026-10-21 — Q3 FY2026 (quarter ended September 25, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Danaher's Q3 2026 sales rose 8.5% to $6.55B, with core sales up 3.0% and acquisitions (led by Masimo) contributing 6.5 points, while operating margin slipped to 19.0%.
Biggest Revenue Drivers
Diagnostics$2.88B+17.0% YoY
Increase primarily as a result of the Masimo Acquisition; core sales rose 0.5% as clinical demand offset lower respiratory testing.
Life Sciences$1.87B+4.0% YoY
Increase primarily driven by increased core sales, led by consumables and higher equipment demand.
Biggest Revenue Drivers
Total revenue: $6.55B+8.5% YoY
Diagnostics$2.88B+17.0% YoY
Increase primarily as a result of the Masimo Acquisition; core sales rose 0.5% as clinical demand offset lower respiratory testing.
Life Sciences$1.87B+4.0% YoY
Increase primarily driven by increased core sales, led by consumables and higher equipment demand.
Biotechnology$1.81B+0.5% YoY
Increase led by increased core sales, partially offset by tariff refunds to customers; currency reduced growth.
Largest Expense Items
Selling, general and administrative expenses$2.16B+8.4% YoY
Increase reflects the Masimo Acquisition and $14M of stock-based compensation on special founder and executive awards.
Cost of sales$2.72B+7.4% YoY
Increase primarily from recently acquired businesses, $84M Masimo inventory fair value adjustment and $52M facility impairment, partly offset by IEEPA tariff refunds.
Margins: Operating margin declined 10 basis points to 19.0% as acquisition-related inventory step-up, Masimo dilution and founder award expense outweighed higher core sales and IEEPA tariff refunds. Gross margin rose to 58.5% from 58.2%.
Watch Items from the Filing
Masimo Apple litigation: a $634M jury verdict plus ~$184M pre-judgment interest is on appeal to the Federal Circuit, with the ITC exclusion order still in effect.
Net debt rose sharply: long-term debt reached $24.4B versus $18.4B at year-end 2025, financing the ~$9.8B Masimo purchase and a further $1.4B StatLab acquisition.
Respiratory testing demand fell; the filing notes upcoming respiratory season severity could further affect molecular diagnostics demand over the rest of 2026.
Q3 net earnings of $1.2B include a $263M discrete tax benefit from audit settlements, which inflated EPS by about $0.37 per diluted share.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Bouda ChristopherVP, Chief Accounting OfficerGrant or award · Aug 4, 2026
Sawyer Montgomery Julie AExecutive Vice PresidentGrant or award · Aug 4, 2026
Leiken JonathanSVP-Chief Legal OfficerGrant or award · Aug 4, 2026
Milosevich Gregory MExecutive Vice PresidentGrant or award · Aug 4, 2026
Gutierrez-Ramos Jose-CarlosSVP, Chief Science OfficerGrant or award · Aug 4, 2026
Gugino Matthew EEVP & Chief Financial OfficerGrant or award · Aug 4, 2026
Riley Christopher PaulExecutive Vice PresidentGrant or award · Aug 4, 2026
Congress trading in DHR
58 transactions in DHR reported by 25 members of Congress under the STOCK Act, most recent trade Sep 2, 2026. Reported transactions, not recommendations.
About DANAHER CORP /DE/ (DHR): stock profile, AI score and financials
DANAHER CORP /DE/ (DHR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DHR at 68.2/100 on a composite quality score built from its SEC filings, placing it at rank #312 of 2,925 stocks — the top 25% of the AI-ranked universe. DHR scores in the top quartile across revenue scale (93.9), profitability (78.1), free cash flow (76.5). Areas of concern include revenue growth (38.7), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q3 2026), DANAHER CORP /DE/ reports quarterly revenue of $6.6B, net income of $1.2B, an operating margin of 19.0%. Top institutional holders of DHR by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, FMR, based on the most recent SEC filings. DHR trades on the NYSE exchange and files with the SEC under CIK 313616. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DHR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DANAHER CORP /DE/ directly from SEC EDGAR.